Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation
Sponsor: Centre Hospitalier St Anne
Summary
This study aims to better understand the mechanisms of action of antidepressants, but also the neural correlates of motivation deficits. One hundred patients with a moderate to severe major depressive episode will be enrolled in this prospective multicenter study. The objective will be to predict the therapeutic response to two first-line antidepressants on the basis of an early neurocomputational assessment of motivation. Antidepressant treatment will be administered as monotherapy after randomization between two drugs: escitalopram and vortioxetine. Patients will undergo six visits and follow-up for one year. The investigators will combine computer modeling and functional MRI to identify motivational deficits and elucidate their brain correlates before initiation, after 7 days and after 6 months of treatment. 36 healthy volunteers will also be included to allow comparison with patients with depression. They will not receive any treatment.
Official title: Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
136
Start Date
2023-09-12
Completion Date
2026-11-12
Last Updated
2024-07-10
Healthy Volunteers
Yes
Conditions
Interventions
escitalopram
Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
vortioxetine
Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
Locations (5)
Groupe hospitalo-universitaire de Grenoble Alpes
La Tronche, Isère, France
Centre hospitalier Universitaire de Lille
Lille, Nord, France
Centre hospitalier Universitaire de Saint-Etienne
Saint-Priest-en-Jarez, Pays de la Loire Region, France
Groupe hospitalo-universitaire Assistance Publique, hôpital Pitié Salpêtrière - Hôpitaux de Paris Sorbonne Université
Paris, France
- Groupe hospitalo-universitaire Paris Psychiatrie et Neurosciences
Paris, France